<DOC>
	<DOCNO>NCT02889497</DOCNO>
	<brief_summary>This study evaluate safety , three batch consistency immunity duration post-marketing inactivate Enterovirus Type 71 ( EV71 ) vaccine child age 6-71 months.This study two group : safety observation group immunogenicity observation group.20000 subject receive 2 dos vaccine observe safety among 2 epidemic cycle HFMD.In immunogenicity observation group , 900 subject randomly receive 3 batch vaccine ( 2 dos ) , blood sample day 0 56 .</brief_summary>
	<brief_title>Safety , Three Batches Consistency Immunity Duration Post-marketing Inactivated Enterovirus Type 71 ( EV71 ) Vaccine Children Aged 6-71 Months</brief_title>
	<detailed_description />
	<mesh_term>Mouth Diseases</mesh_term>
	<mesh_term>Foot-and-Mouth Disease</mesh_term>
	<mesh_term>Hand , Foot Mouth Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>8 Months 71 Months ( Healthy Children Infants ) ； Providing subject ' legal identity certificate ( birth certificate , residence booklet ID card ) vaccination certificate , legal guardian provide legal identity proof ( resident booklet ID card ) doctor determine subject identity complete recruitment program； The subject ' guardian able understand sign inform consent voluntary . Guardians ability use thermometer , divide ruler fill Diary card , followup card accord requirements； Persist 24 month visit.If doubtful HFMD case happen，the subject 's guardian send subject medical institution county level report case investigator.The subject participate immunogenicity observation group receive sample collection include blood，throat swab anal awab accord program requirement . Exclusion Criteria first dose : Subject clinical diagnosis suspect HFMD（Especially history herpangina）； Subject medical history following : allergic history , allergic ingredient vaccine； History seizure , convulsion twitch ; Family history progressive neurological disease； Autoimmune disease immunologic deficiency.Any prior administration immunodepressant last 6month； History asthma，thyroid ablation，angioneurotic edema , diabetes mellitus malignant tumour； Alienia，functional asplenia，or condition cause asplenia splenectomy； Diagnosed coagulation abnormality ( clot factor deficiency , coagulation disorder , platelet disorder ) significant bruise blood clot disorder； Any acute disease chronic disease attack last 7 days； Any prior administration blood product last 3 month； Any prior administration attenuate live vaccine last 15 day , subunit inactivate vaccine last 7 days； Fever vaccination , axillary temperature ﹥37.0℃； Attend Other vaccine drug clinical trial concurrent 6 months； Any condition opinion investigator。 Exclusion Criteria second dose : Any exclusion criterion first dose happens enrolled； Newly HFMD diagnose patient enrolled； Any condition opinion investigator ethic committee think eliminate .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>71 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>